Education
About Us
Working with TipRanks
Follow Us
Sysmex Corporation (JP:6869)
:6869
Top Page
Sysmex
(OTC:6869)
75Outperform
Sysmex (6869) vs. S&P 500 (SPY)
Market Cap
$1.66T
Dividend Yield1.07%
Average Volume (3M)1.35M
Price to Earnings (P/E)28.8
Beta (1Y)0.79
Revenue Growth14.50%
EPS Growth29.02%
CountryJP
Employees10,042
SectorHealthcare
Sector Strength69
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)26.65
Shares Outstanding629,469,300
10 Day Avg. Volume1,461,490
30 Day Avg. Volume1,345,393
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3,396.12Price Target Upside28.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Sysmex Business Overview & Revenue Model
Company DescriptionSysmex Corporation (6869) is a leading global company headquartered in Japan that specializes in the development, production, and distribution of diagnostic instruments, reagents, and software. The company primarily operates within the healthcare sector, focusing on laboratory testing and diagnostics. Sysmex's core products include hematology analyzers, urinalysis analyzers, and other clinical diagnostic equipment, which are used in hospitals, laboratories, and research institutions worldwide.
How the Company Makes MoneySysmex makes money by selling diagnostic instruments, reagents, and software solutions primarily to healthcare providers, including hospitals and clinical laboratories. The company's revenue model is centered around the sale of its innovative diagnostic equipment, which is often complemented by consumable reagents required for the operation of these machines. Additionally, Sysmex generates income through maintenance services and customer support for its products. The company also benefits from strategic partnerships and collaborations with other healthcare and biotechnology firms, which enhance its product offerings and market reach. Its global presence and continuous investment in R&D contribute to its strong market position and sustained revenue growth.
Sysmex Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 501.85B | 461.51B | 410.50B | 363.78B | 305.07B | 301.98B | Gross Profit |
| 269.53B | 242.50B | 216.08B | 190.59B | 154.30B | 159.81B | EBIT |
| 90.96B | 78.38B | 73.68B | 67.42B | 51.79B | 55.28B | EBITDA |
| 126.96B | 115.67B | 104.95B | 96.12B | 75.53B | 74.28B | Net Income Common Stockholders |
| 57.79B | 49.64B | 45.78B | 44.09B | 31.90B | 34.88B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 81.94B | 76.61B | 70.33B | 75.25B | 67.57B | 57.01B | Total Assets |
| 652.39B | 618.92B | 531.07B | 483.71B | 427.48B | 389.29B | Total Debt |
| 60.17B | 55.34B | 22.59B | 22.28B | 21.96B | 22.64B | Net Debt |
| -21.77B | -20.17B | -46.87B | -51.47B | -44.51B | -33.96B | Total Liabilities |
| 188.77B | 186.02B | 142.72B | 134.65B | 118.81B | 110.94B | Stockholders Equity |
| 462.88B | 432.05B | 387.67B | 348.30B | 307.90B | 277.68B |
| Cash Flow | Free Cash Flow | ||||
| 52.41B | 13.71B | 26.33B | 26.70B | 33.02B | 26.71B | Operating Cash Flow |
| 83.96B | 63.91B | 68.83B | 58.74B | 58.81B | 53.18B | Investing Cash Flow |
| -47.26B | -54.97B | -51.75B | -35.05B | -31.13B | -25.91B | Financing Cash Flow |
| -20.83B | -9.01B | -24.23B | -20.54B | -20.25B | -20.60B |
Sysmex Technical Analysis
Negative
2650.00
Price Trends
2737.85
Negative
2850.19
Negative
2791.86
Negative
Market Momentum
-29.00
Positive
44.43
Neutral
29.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6869, the sentiment is Negative. The current price of 2650 is below the 20-day moving average (MA) of 2709.47, below the 50-day MA of 2737.85, and below the 200-day MA of 2791.86, indicating a bearish trend. The MACD of -29.00 indicates Positive momentum. The RSI at 44.43 is Neutral, neither overbought nor oversold. The STOCH value of 29.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6869.
Sysmex Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $3.96T | 31.74 | 9.39% | 0.96% | 14.23% | 26.82% | |
75 Outperform | $1.66T | 28.76 | 13.12% | 1.07% | 14.50% | 29.02% | |
74 Outperform | $3.44T | 13.71 | 7.77% | 2.31% | 7.29% | 4.85% | |
69 Neutral | $2.01T | 24.47 | 12.71% | 1.03% | 7.60% | -66.30% | |
65 Neutral | $1.14T | 19.61 | 6.83% | 3.69% | 5.63% | 30.61% | |
64 Neutral | ¥4.14T | 23.96 | 3.61% | 9.08% | -33.61% | ||
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% |
* Healthcare Sector Average
Performance Comparison
JP:6869
Sysmex
2,660.50
199.32
8.10%
JP:7751
Canon Inc.
4,332.00
248.43
6.08%
JP:4901
FUJIFILM Holdings
2,858.50
-410.28
-12.55%
JP:4543
Terumo
2,719.00
132.96
5.14%
JP:4523
Eisai Co
4,073.00
-1,964.56
-32.54%
JP:7733
Olympus
1,819.00
-333.95
-15.51%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.